Two-stage design & RSABE: Forget it! [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2021-05-19 20:40 (68 d 05:38 ago) – Posting: # 22357
Views: 408

Hi Achievwin,

» 1) is there a precedence of conducting two stage study for 4-period full replicate design? (four periods in stage 1 and stage 2)

I have seen one since 2010. Not for RSABE but for the EMA’s ABEL. Asymmetric alphas – don’t remember which approach: Haybittle-Peto (0.001/0.049) or O’Brien/Fleming (0.005/0.048). Even in a 2×2×2 crossover TSD there is an inflated Type I Error. This study ended in a – vested – deficiency letter of the MHRA.

“The applicant has to demonstrate that the patient’s risk is controlled.”

Oops!

» 2) what kind of penalty we can factor in?

That’s not the point and should be the least of your worries. Unless you have a magic wand providing you with a suitable adjusted α, no way.
Did you bother to read that (already linked in my previous post)?

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,589 posts in 4,512 threads, 1,530 registered users;
online 5 (0 registered, 5 guests [including 2 identified bots]).
Forum time: Tuesday 02:18 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5